NCT00816478View on ClinicalTrials.gov

Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor

PHASE1TerminatedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions

Focal Segmental Glomerulosclerosis

Interventions

DRUG

Galactose

Oral galactose, 0.2 g/kg/dose twice daily for 28 days

Sponsors

Lead Sponsor

Northwell Health

All Listed Sponsors

lead

Northwell Health

OTHER